Background
==========

The metabolic syndrome (MS) is a cluster of the most dangerous risk factors for type 2 diabetes mellitus and cardiovascular disease (CVD), including abdominal obesity, hypertension, hyperglycemia and dyslipidemia. When these metabolic abnormalities occur in the same individual they confer an additional cardiovascular risk above and beyond the contribution of the individual components \[[@B1],[@B2]\]. It is estimated that the risk from the MS for major cardiovascular events is approximately twice as high as for those with the syndrome compared to those without it, and the risk for type 2 diabetes is around five-fold greater for those with the MS \[[@B2]-[@B4]\].

The MS is becoming epidemic around the world and the prevalence of the MS has been estimated to be more than 20%. The high prevalence of the MS has been reported not only in developed countries \[[@B5]-[@B7]\] but also in developing regions \[[@B8],[@B9]\], including China \[[@B10]-[@B13]\]. China has experienced a remarkable economic expansion in the past three decades, and Pudong New Area of Shanghai is one of the most economically active areas in the country. This area of Shanghai has experienced a rapid nutrition transition characterized by an increasingly sedentary lifestyle and substantial dietary changes (e.g., increasingly energy-density) \[[@B14]\], as well as a dramatic aging of the population \[[@B15]\]. These changes are likely to have contributed to a high prevalence of the MS and increased risk for type 2 diabetes, CVD and premature death. In order to evaluate and predict the burden of CVD and other chronic diseases in this area, population-based estimates of the prevalence of the MS are needed.

So far, however, there has been no definition of the MS accepted universally. Currently, several definitions of the MS have been proposed for use, and each definition has a slightly different emphasis. While the one proposed by World Health Organization takes insulin resistance as a required component \[[@B16]\], the modified ATP III criteria treat the five components equally \[[@B17]\]. The IDF definition, on the other hand, puts an emphasis on central obesity \[[@B18]\]. Due to the lack of internationally agreed-upon criteria to define the condition, the prevalence of the MS has varied widely across different studies. Comparisons between the prevalence of the MS using these definitions may help better understand the characteristics of metabolic disorder among Chinese adults and facilitate interventions to prevent the MS and subsequent development of CVD.

In this study, we estimated and compared the prevalence of the MS by applying the three definitions of the condition in a representative sample of the residents in Pudong New Area of Shanghai, China.

Methods
=======

Participants of the study
-------------------------

This cross-sectional study was conducted from April to July of 2008 among permanent residents of Pudong New Area of Shanghai, China, who had lived in the area for 5 years or more. A total of 6,387 eligible adults (20-79 yrs) were randomly selected from the area using a three-stage sampling design. Firstly, all 30 streets in this area were classified into three groups (each with 10 streets) according to the residents\' average social economic status \[[@B14]\] and 12 streets (4 from each group) were randomly selected. Then, a total of 34 communities, which hold about 71,000 eligible residents, were randomly selected from the 783 communities in the selected streets. The expected number of participants in each community was calculated as 9.0% of its eligible population. Finally, a house number was randomly selected in each community as the first family interviewed. All eligible subjects in the selected families were recruited. Pregnant women and physically or mentally disabled persons were excluded from the survey. Of the 6,387 eligible adults contacted, 5,584 were interviewed and donated blood and urine samples, yielding a response rate of 87.4%. Of these participants, 2,477 were male and 3,107 were female, and 804 non-participants (12.6%) declined to be interviewed for miscellaneous reasons. The study was approved by Fudan University Institutional Review Board (IRB00002408, FWA00002399).

Data collection
---------------

After obtaining written consent, a structured in-person interview was conducted by trained interviewers to elicit information about demographic factors, diagnosis of hypertension, diabetes and hyperlipidemia, tobacco and alcohol use, physical activity, and family history of hypertension and diabetes. At the interview, each participant was also measured for his/her blood pressure, body weight, standing height, and circumference of the waist and hip by trained staff. Blood pressure (BP) was measured on the right arm in the sitting position using standard mercury sphygmomanometer after at least 5 minutes of rest. The first and fifth Korotkoff sounds were recorded. Body height was measured to the nearest 0.1 cm by using a stadiometer. Girth measurements, recorded to the nearest 0.1 cm, were taken with a cloth tape. Waist circumference (WC) was measured at the midline between the lower border of the ribs and the iliac crest (usually at a level of 2.5 cm above the umbilicus) in the horizontal plane after a normal expiration. Hip circumference was defined as the maximum girth reading between waist and thigh. Body weight was measured with electronic scales to the nearest 0.1 kg. Two measurements were taken, with tolerances of \<5 mmHg for blood pressure, \<1 cm for height and circumference, and \<1 kg for weight. A third measurement was taken if the difference between the first two exceeded the tolerance. The mean of the replicates was used in the following analyses. Body mass index (BMI: weight in kilograms divided by height in meters squared, kg/m^2^) and waist-to-hip circumference ratio (WHR) were calculated using the direct measurements.

Laboratory measurements
-----------------------

All participants were asked to provide 10 ml fasting blood and 50 ml morning void urine for biochemical analysis in Shanghai Second People\'s Hospital. An automatic Biochemical Analyzer (HITACHI 7170A, Hitachi, Ltd, Tokyo, Japan) was used to measure the levels of fasting plasma glucose (FPG), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC), as well as urinary concentrations of creatinine and albumin by using enzymology or immunoradiometry methods. Quality control of the assays was assessed internally and externally. The interassay coefficient of variation was \<1.5% for FPG, \<1.6% for TG, \<3.0% for TC, \<2.9% for HDL-C, \<1.6% for LDL-C, \<7.0% for urinary album, and \<2.1% for urinary creatinine.

Definitions of the metabolic syndrome
-------------------------------------

The WHO criteria \[[@B16]\] for the MS required the presence of diabetes mellitus or impaired fasting plasma glucose (FPG ≥ 5.6 mmol/L) and at least two of the following components: 1) diagnosed with hypertension or blood pressure: ≥ 140/90 mmHg; 2) dyslipidemia: TG ≥ 1.695 mmol/L or HDL-C ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female); 3) central obesity: WHR \> 0.90 (male); \> 0.85 (female), or BMI ≥ 30 kg/m^2^; or 4) microalbuminuria: urinary albumin to creatinine ratio (ACR) ≥ 30 mg/g.

The modified ATP III definition of the MS \[[@B17]\] required the presence of at least 3 or more of the following 5 components: 1) elevated WC: ≥ 90 cm (male), ≥ 80 cm (female); 2) elevated TG: \> 150 mg/dL (1.695 mmol/L); 3) reduced HDL-C: \< 1.036 mmol/L (male), \< 1.295 mmol/L (female); 4) hypertension or elevated BP: ≥ 130/85 mmHg; or 5) diabetes or elevated FPG: ≥ 5.6 mmol/L.

The 2006 International Diabetes Federation (IDF) definition classified a person with the MS in the same way as ATP III, but required the presence of central adiposity (elevated WC) as an essential component \[[@B18]\].

Statistical analysis
--------------------

Statistical analysis was conducted using SAS (version 8.1; SAS Institute, Cary, NC). Chi-square and student *t*tests were used to compare the difference between categorical and numeric variables. Age-standardized prevalence of the MS was calculated based on the age distribution of the standard world population. Logistic regression models were fit to evaluate the association of individual metabolic abnormalities with the MS. In addition, kappa statistics were calculated to determine the level of agreement between the three MS definitions. P values \< 0.05 were considered statistically significant.

Results
=======

Measured metabolic characteristics of the study population
----------------------------------------------------------

Table [1](#T1){ref-type="table"} presents the measured metabolic characteristics in our population. Compared to women, men had a significantly higher WC, WHR, BMI, higher systolic and diastolic BP and higher levels of FPG and TG. Men also had lower levels of HDL-C and ACR than women. The differences between men and women in prevalence of elevated BMI or WC were not significant, but men had a higher prevalence of elevated BP, FPG and TG, while women had a higher prevalence of low HDL-C and elevated ACR (Table [1](#T1){ref-type="table"}).

###### 

Measured metabolic characteristics of the selected Chinese adults in Pudong New Area of Shanghai, China

  Characteristics             Male (N = 2477)   Female (N = 3107)   P value
  --------------------------- ----------------- ------------------- ----------
  *WC*                                                              
  Mean ± SD                   83.9 ± 9.2        78.3 ± 9.4          \<0.0001
  ≥ 90 cm for male            22.1                                  
  ≥ 80 cm for female                            38.5                \<0.0001
  *BMI*                                                             
  Mean ± SD                   24.1 ± 3.3        23.8 ± 3.5          \<0.0001
  ≥ 30 kg/m^2^                4.5               5.3                 0.16
  *WHR*                                                             
  Mean ± SD                   0.88 ± 0.06       0.83 ± 0.07         \<0.0001
  \>0.90 for male             38.3                                  
  \>0.85 for female                             37.9                0.93
  *Systolic BP*                                                     
  Mean ± SD                   128 ± 16.1        126 ± 19.6          \<0.0001
  ≥ 130 mmHg                  40.3              37.5                0.03
  *Diastolic BP*                                                    
  Mean ± SD                   81 ± 9.5          80 ± 10.1           \<0.0001
  ≥ 85 mmHg                   27.0              24.6                0.05
  *FPG*                                                             
  Mean ± SD                   5.8 ± 1.9         5.7 ± 1.6           0.0003
  \>5.6 mmol/l                35.9              31.4                0.0006
  *HDL-C*                                                           
  Mean ± SD                   1.34 ± 0.26       1.48 ± 0.27         \<0.0001
  \<1.036 mmol/l for male     11.1                                  
  \<1.295 mmol/l for female                     25.8                \<0.0001
  *TG*                                                              
  Mean ± SD                   2.4 ± 2.1         2.1 ± 1.7           0.0001
  \>1.695 mmol/l              56.5              47.0                \<0.0001
  *Urinary ACR*                                                     
  Mean ± SD                   2.0 ± 9.2         2.8 ± 11.1          \<0.0001
  ≥ 30 mg/g                   0.8               1.6                 0.0035

P value for *t*-test (continuous variables) or χ^2^test (categorical variables).

Sex and age-specific prevalence of the MS in the study population
-----------------------------------------------------------------

The prevalence of the MS was observed to increase with increasing age in both sexes by either one of the three definitions. It is of note that the age-specific prevalence was higher in men than in women in early adulthood (before age of 65 according to WHO definition and at age of 40 using ATP III and IDF criteria) but appeared lower during elderly period (Table [2](#T2){ref-type="table"}). The MS was more common in men (20.2%) than in women (18.7%) using WHO definition but was otherwise according to modified ATP III (28.4% for men vs. 35.1 for women) and IDF (15.9% for men vs. 26.7% for women) criteria.

###### 

Sex and age-specific prevalence of the MS according to WHO, modified ATP III and IDF definition among selected Chinese adults in Pudong New Area of Shanghai, China

             No. of Subjects   WHO criteria   ATP III criteria   IDF criteria                      
  ---------- ----------------- -------------- ------------------ -------------- ------------ ----- ------------
  *Male*                                                                                           
             2477              498            20.2(15.3)         696            28.4(22.7)   391   15.9(13.8)
  20-        141               3              2.1                10             7.1          9     6.4
  25-        124               6              4.9                17             14.1         14    11.6
  30-        134               8              6.1                16             12.2         12    9.2
  35-        142               22             15.8               26             18.7         17    12.2
  40-        204               35             17.2               54             26.7         34    16.8
  45-        314               55             17.5               74             23.7         38    12.2
  50-        309               76             19.6               114            29.5         61    15.8
  55-        348               85             24.6               117            33.9         61    17.7
  60-        258               80             31.3               103            40.2         51    19.9
  65-        162               51             31.7               68             42.5         38    23.8
  70-        173               44             25.4               62             35.8         34    19.7
  75-        88                33             37.5               35             40.2         22    25.3
  *Female*                                                                                         
             3107              575            18.7(12.3)         1078           35.1(25.0)   821   26.7(19.2)
  20-        159               0              0                  3              1.9          3     1.9
  25-        176               3              1.8                15             8.8          14    8.2
  30-        156               3              1.9                13             8.4          10    6.5
  35-        186               8              4.4                33             17.9         28    15.2
  40-        274               20             7.4                48             17.8         34    12.6
  45-        395               59             15.0               113            28.8         83    21.1
  50-        551               98             17.9               205            37.6         149   27.3
  55-        468               123            26.5               210            45.2         172   37.0
  60-        265               80             30.2               147            55.5         110   41.5
  65-        189               59             31.9               96             52.5         71    38.8
  70-        188               75             39.9               130            69.5         99    52.9
  75-        100               47             47.5               65             65.7         48    48.5

In parentheses was the age-standardized prevalence of the MS according to age distribution of the world population.

Prevalence of individual metabolic abnormalities in the study population
------------------------------------------------------------------------

The prevalence of individual metabolic abnormalities is presented in Table [3](#T3){ref-type="table"}. According to WHO criteria, dyslipidemia, i.e. elevated TG or reduced HDL-C, was the most common metabolic abnormality in both men (56.9%) and women (47.8%), followed by central obesity, elevated FPG, raised BP and presence of microalbuminuria. Among the five metabolic abnormalities defined by modified ATP III or IDF criteria, elevated TG also ranked first in both sexes (59.2% for men and 49.7% for women), followed by elevated BP (49.0% for men and 44.8% for women), elevated FPG (36.7% for men and 32.2%), increased WC (22.1% for men and 38.5 for women) and reduced HDL-C (11.1% for men and 19.3% for women). In this population, the present of 1 or 2 metabolic abnormalities was most common in both men and women.

###### 

Prevalence of individual metabolic abnormalities among selected Chinese adults in Pudong New Area of Shanghai, China

  --------------------------------------- ------ ------ ------ ------ ------ ------
  *By WHO criteria*                                                          
   Impaired FPG or diabetes               903    36.7   992    32.2   1895   34.2
   Central obesity                        973    39.3   1224   39.4   2197   39.3
   Elevated BP or hypertension            778    31.4   927    29.8   1705   30.5
   Microalbuminuria                       19     0.8    51     1.6    70     1.3
   Hyperlipidemia                         1409   56.9   1485   47.8   2894   51.8
   No. of metabolic abnormalities                                            
    0                                     483    19.6   859    27.9   1342   24.2
    1                                     682    27.7   791    25.7   1473   26.6
    2                                     675    27.4   696    22.6   1371   24.8
    3                                     455    18.5   495    16.1   950    18.2
    4                                     161    6.5    226    7.3    387    7.0
    5                                     4      0.2    13     0.4    17     0.3
  *By modified ATP III or IDF criteria*                                      
   Increased WC                           548    22.1   1196   38.5   1744   31.2
   Elevated BP or hypertension            1213   49.0   1393   44.8   2606   46.7
   Reduced HDL-C or use drug              272    11.1   795    25.8   1067   19.3
   Elevated TG or use drug                1455   59.2   1532   49.7   2987   54.0
   Impaired FPG or diabetes               903    36.7   992    32.2   1895   34.2
   No. of metabolic abnormalities                                            
    0                                     418    17.0   667    21.7   1085   19.6
    1                                     663    27.0   677    22.0   1340   24.2
    2                                     676    27.6   652    21.2   1328   24.0
    3                                     460    18.8   557    18.1   1017   18.4
    4                                     206    8.4    385    12.5   591    10.7
    5                                     30     1.2    136    4.4    168    3.0
  --------------------------------------- ------ ------ ------ ------ ------ ------

Prevalence of the MS among subjects with a certain metabolic abnormality
------------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows the prevalence of MS estimated by each definition in all participants and among subjects with a specific metabolic abnormality. The prevalence of the MS was 40.0% for the men and 34.5% for the women with elevated WC using WHO definition, but the prevalence estimated was substantially greater when using the modified ATP III (71.6%) and IDF criteria (69.3%). Among the subjects with high BP, only 32.5% of the men and 34.1% of the women had the MS using the WHO definition whereas 50.0% of the men and 63.2% of the women were classified as such according to the modified ATP III definition. Difference in the prevalence of MS was also observed among subjects having other individual metabolic abnormalities.

![**Prevalence of the MS according to WHO, modified ATP III and IDF criteria in all participants and the subjects with each individual metabolic abnormality**.](1471-2458-10-246-1){#F1}

Association of individual metabolic abnormalities with the MS
-------------------------------------------------------------

We also examined the association of the individual metabolic abnormalities with the MS. Subjects with any one metabolic disorder were more likely to be diagnosed with the MS by modified ATP III definition (Table [4](#T4){ref-type="table"}). Microalbuminuria, one component of the WHO criteria, was strongly associated with the condition in both sexes, but was not significantly related to the MS in men using the definitions of the ATP III or IDF. Interestingly, regardless of the definition used, subjects with elevated TG were most likely to be diagnosed with the MS, with odds ratios (OR) being 7.6, 15.9 and 5.1 for men and 7.3, 16.5 and 7.7 for women under WHO, ATPIII and IDF definition, respectively, after adjusting for age, BMI, alcohol consumption, cigarette smoking and exercise.

###### 

Association of individual metabolic abnormalities with the MS among selected Chinese adults in Pudong New Area of Shanghai, China

  ---------------------------------------------------------- ---------- --------------- ----------- ----------------- ---------- --------------
  *Male*                                                                                                                         
  Impaired FPG or diabetes                                                                                                       
   No                                                        1557/0     \--             1379/176    1.0               1413/142   1.0
   Yes                                                       405/498    \--             377/521     9.6(7.8-11.9)     648/250    3.5(2.8-4.4)
  Central obesity (WC \> 90 cm)                                                                                                  
   No                                                        1632/279   1.0             1602/305    1.0               1907/0     \--
   Yes                                                       329/219    3.9(3.1-4.8)    154/392     14.9(11.8-18.9)   154/392    \--
  Hypertension or elevated BP (sbp ≥ 130 or dbp ≥ 85 mmHg)                                                                       
   No                                                        1143/107   1.0             1151/96     1.0               1170/77    1.0
   Yes                                                       819/391    4.1(3.2-5.2)    605/601     10.7(8.4-13.7)    891/315    5.1(3.9-6.7)
  Microalbuminuria                                                                                                               
   No                                                        1956/485   1.0             1748/687    1.0               2049/386   1.0
   Yes                                                       6/13       6.8(2.5-18.7)   8/10        2.4(0.9-6.1)      12/6       2.1(0.8-5.8)
  Reduced HDL-C or use drug^a^                                                                                                   
   No                                                        1770/416   1.0             1681/502    1.0               1893/290   1.0
   Yes                                                       192/80     1.5(1.1-2.0)    75/195      9.9(7.2-13.8)     168/102    3.2(2.3-4.6)
  Elevated TG or use drug^a^                                                                                                     
   No                                                        950/50     1.0             950/49      1.0               953/46     1.0
   Yes                                                       1009/446   7.6(5.5-10.4)   806/648     15.9(11.3-22.2)   1108/346   5.1(3.5-7.4)
  Dyslipidemia (reduced HDL-C or elevated TG)^a^                                                                                 
   No                                                        1007/60    1.0             986/76      1.0               1001/61    1.0
   Yes                                                       955/438    7.4(5.5-10.0)   770/621     10.9(8.2-14.6)    1060/331   4.2(3.0-5.8)
  *Female*                                                                                                                       
  Impaired FPG or diabetes                                                                                                       
   No                                                        2088/0     \--             1706/380    1.0               1757/329   1.0
   Yes                                                       417/575    \--             288/700     8.4(7.0-10.1)     495/493    3.9(3.3-4.7)
  Central obesity (WC \> 85 cm)                                                                                                  
   No                                                        1427/166   1.0             1631/258    1.0               1889/0     \--
   Yes                                                       778/409    4.0(3.3-4.9)    363/822     12.0(10.0-14.5)   363/822    \--
  Hypertension or elevated BP (sbp ≥ 130 or dbp ≥ 85 mmHg)                                                                       
   No                                                        1590/103   1.0             1484/205    1.0               1515/174   1.0
   Yes                                                       915/472    4.9(3.8-6.2)    510/875     8.3(6.8-10.0)     737/648    5.3(4.3-6.5)
  Microalbuminuria                                                                                                               
   No                                                        2489/540   1.0             1983/1040   1.0               2235/788   1.0
   Yes                                                       16/35      7.8(4.0-15.3)   11/40       5.3(2.5-11.2)     17/34      4.1(2.2-7.8)
  Reduced HDL-C or use drug^a^                                                                                                   
   No                                                        1951/333   1.0             1738/543    1.0               1841/440   1.0
   Yes                                                       553/241    2.3(1.8-2.8)    256/537     10.4(8.2-13.1)    411/382    4.0(3.2-5.0)
  Elevated TG or use drug^a^                                                                                                     
   No                                                        1485/62    1.0             1432/115    1.0               1440/107   1.0
   Yes                                                       1017/511   7.3(5.4-9.7)    562/965     16.5(12.9-21.2)   812/715    7.7(6.0-9.9)
  Dyslipidemia (reduced HDL-C or elevated TG)^a^                                                                                 
   No                                                        1547/73    1.0             1456/161    1.0               1475/142   1.0
   Yes                                                       958/502    7.1(5.4-9.4)    538/919     12.1(9.7-15.2)    777/680    5.9(4.7-7.5)
  ---------------------------------------------------------- ---------- --------------- ----------- ----------------- ---------- --------------

OR: Adjusted for age as a continuous variable.

^a^additionally adjusted for BMI (as a continuous variable), cigarette smoking (Never/Ever), alcohol consumption (Never/Ever) and exercise (Never/ever).

Agreement between the three MS definitions
------------------------------------------

Figure [2](#F2){ref-type="fig"} shows the overall prevalence of the MS by WHO, modified ATP III and IDF criteria. Nine percent of men and 13.3% of women were consistently classified as having the MS by each definition and 68.6% of men and 64.1% of women were classified as being free from the MS consistently. The level of agreement between each two definitions was modest, with kappa value ranging from 0.382 to 0.806 (Table [5](#T5){ref-type="table"}). Agreement between modified ATP III and IDF criteria was substantial with a kappa of 0.647 for men and 0.806 for women. All subjects classified with the MS by the IDF definition were also classified this way by the ATP III criteria. The lowest level of agreement was between the WHO and IDF definitions in both men (κ = 0.382) and women (κ = 0.469).

###### 

Agreement of WHO, modified ATP III and IDF criteria in identifying the MS among selected Chinese adults in Pudong New Area of Shanghai, China

                      WHO criteria   κ      95%CI   ATP III criteria   κ     95%CI           
  ------------------- -------------- ------ ------- ------------------ ----- ------- ------- -------------
  *Male*                                                                                     
   ATP III criteria                                                                          
    +                 434            276                               \--   \--             
    -                 73             1670   0.617   0.611-0.622        \--   \--     \--     
   IDF criteria                                                                              
    +                 220            177                               397   0               
    -                 287            1769   0.382   0.377-0.387        313   1743    0.647   0.643-0.652
  *Female*                                                                                   
   ATP III criteria                                                                          
    +                 553            532                               \--   \--             
    -                 27             1962   0.552   0.547-0.558        \--   \--     \--     
   IDF criteria                                                                              
    +                 413            414                               827   0               
    -                 167            2080   0.469   0.464-0.474        258   1989    0.806   0.802-0.810

P \< 0.01 for all κ statistics.

![**Overall prevalence of the MS among selected Chinese adults in Pudong New Area of Shanghai, China, according to WHO, modified ATP III and IDF criteria**.](1471-2458-10-246-2){#F2}

Discussion
==========

In this representative sample of adults whose age and sex distribution was similar to that in Pudong New Area of Shanghai, China \[[@B19]\], we found that the MS was highly prevalent. Using the modified criteria of ATP III for the MS the prevalence was 28.4% for men and 35.1% for women. The overall and age-specific prevalence of the MS in this population were much higher than the general levels of Chinese adults in 1992 and 2000-01 \[[@B20],[@B21]\], and were similar to those in other economically developed areas in China \[[@B11],[@B13]\]. In fact, the prevalence of the MS was comparable to those in developed countries \[[@B5],[@B22]\].

Consistent with the results from studies in other populations \[[@B5],[@B13],[@B22]\], the prevalence of the MS increased with age in both sexes in our study. We observed a wide discrepancy between the crude and age-standardized prevalence of the MS, indicating that the increasing proportion of older adults in the population has contributed much to the overall prevalence of the MS in this area. The number of adults at age 60+ years in Shanghai reached 3.0 million in 2008, and they account for more than 20 percent of all residents in the city \[[@B23]\]. Interestingly, in early adulthood the age-specific prevalence was higher in men than in women but this pattern was reversed among older adults. The age-specific prevalence pattern we observed was consistent with that in a Japanese population \[[@B24]\], but differed from several other previous studies, in which a higher age-specific prevalence of the MS was consistently observed for women \[[@B5],[@B10],[@B11]\]. The explanation for this finding is not immediately clear, and the pattern varied by the definition employed. It is possible that the men in Shanghai were at a higher risk of the MS than women, and thus had a higher mortality from CVD and diabetes in later adulthood. In addition, selection biases and chance cannot be excluded. Notably, the cross-over point of the sex specific prevalence estimates by age was much later in life when the WHO definition was used (about age 65), compared to the modified ATP III or IDF criteria (about age 40). This may explain the higher overall prevalence of the MS in men using WHO but the higher prevalence estimates in women according to modified ATP III and IDF criteria.

Another significant finding in this study is that dyslipidemia, particularly hypertriglyceridemia, is the most common metabolic disorder in our population. This finding is much different from those of a national estimate from all of China \[[@B10]\], even after taking age differences and the MS definitions used in the two studies into account. The differences in MS components may be due to differences in behavioral risk factors (i.e. diet or lifestyle) rather than genetic susceptibility. The rapid \"nutrition transition\" in Shanghai, characterized by a more sedentary lifestyle and an energy-dense higher fat diet may, at least in part, account for the higher prevalence of hyperlipidemia in our population. This element of the \"nutrition transition\" is a central contributor of hyperlipidemia \[[@B25]\] and may function as initiation factor for the MS \[[@B26]\].

Importantly, the distinct characteristic of the metabolic disorder in this population may indicate predictive value of the MS for the risk of CVD and other chronic diseases in the area. The definitions of the MS, either proposed by WHO, ATP III or IDF, similarly focus on obesity, hypertension, hyperglycaemia and dyslipidemia. The MS is usually identified by the presence of at least 3 of 5 metabolic abnormalities. It is thus plausible that the characteristics of the MS vary across populations. For example, blacks in the US are more likely than the whites to have the clustering of obesity, hypertension and diabetes but less likely to have either elevated TG or low HDL-C levels, leading to a lower prevalence of the MS but higher rates of diabetes and CVD in the blacks than in the whites \[[@B27]\]. If it is true that dyslipidemia is less important in predicting the diabetes and CVD than other metabolic disorders, as suggested by Sumner *et al*\'s \[[@B27]\], the fact that dyslipidemia is the most common metabolic abnormality in our population may indicate and account for the comparable prevalence of the MS but a lower incidence of diabetes and CVD in Chinese adults than in their western counterparts.

The level of agreement we observed among the three definitions was modest and not surprisingly the prevalence of the MS was quite different according to each individual definition employed. This finding is consistent with previous studies conducted in Chinese adults \[[@B13],[@B21]\], and other populations \[[@B6],[@B7],[@B28]-[@B30]\]. Although 68.6% of the men and 64.1% of the women were consistently classified as being free of MS by all 3 definitions, only 9.0% of men and 13.3% of women were consistently classified with the MS by all three criteria. More than 20% of the participants were classified differently using the three definitions. In addition, the prevalence of the MS varied greatly among the subjects with specific individual metabolic abnormalities depending on the definition employed. This reflects that the three definitions have their own respective emphasis. The WHO definition directly assigns greatest value to insulin resistance which is usually indicated by impaired fasting glucose. In contrast, the modified ATP III and IDF definitions do not employ insulin resistance as a required component based on the assumption that the other four components of the MS are linked to insulin resistance. However, significant proportions of those with the four individual components in our sample did not evidence of have insulin resistance as indicted by the criteria employed. For example, there is evidence suggesting no strong link between hypertension and insulin resistance \[[@B31]\]. The phenomenon may explain the discrepancy in the prevalence of the MS in the same population estimated by three definitions. A single worldwide definition of the MS would be desirable to make comparisons between different populations easier and for clinical, epidemiologic and surveillance purposes. There is a need for existing cohort studies in Asia to explore the best and most predictive definition of the MS and its components.

An important limitation of the present study is the cross-sectional design. This fact limited our ability to examine the most predictive MS definition for the risk of diabetes, CVD and premature death among Chinese adults. Moreover, the prevalence of the MS by WHO criteria might be underestimated in this study because impaired fasting glucose was used as the surrogate of impaired glucose tolerance which is more common in Chinese adults \[[@B32]\]. Finally, we cannot exclude problems associated with selection bias from the study, although our response rate to the study was quite high (89.4%). The strengths of this study include the representative sample population, large sample size, and our rigorously standardized methods for measuring the MS components.

Conclusion
==========

In summary, this cross-sectional study shows that the MS characterized with dyslipidemia is highly prevalent in adult population in Pudong New Area of Shanghai, China. The ongoing nutrition transition in this area and the aging of the population may have caused and will aggravate this problem in future years. Given the relatively high prevalence estimates regardless of the definition used, there is a need for a unified definition of the MS in Chinese adults that may guide prevention and treatment efforts to fight against the growing MS epidemic in China.
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